Ganitumab

• CAT Number: I042420
• CAS Number: 905703-97-1
• Purity: ≥95%

Ganitumab (Cat No.: I042420) is a fully human monoclonal antibody that targets the insulin-like growth factor 1 receptor (IGF-1R), a receptor involved in cell proliferation, survival, and resistance to apoptosis. By blocking IGF-1R signaling, ganitumab inhibits downstream pathways such as PI3K/AKT and MAPK, which are often dysregulated in cancer. It has been evaluated in clinical trials for various malignancies, including pancreatic, colorectal, and Ewing sarcoma. Ganitumab is a promising therapeutic candidate for targeting IGF-1R-driven tumor growth and enhancing cancer treatment efficacy.

Reference

[1]. Moody G, et, al. IGF1R blockade with ganitumab results in systemic effects on the GH-IGF axis in mice. J Endocrinol. 2014 Mar 17;221(1):145-55.
[Content Brief]